Greenwich LifeSciences Inc. is a clinical-stage biopharmaceutical enterprise focused on the development of novel immunotherapies designed to prevent breast cancer recurrences and other types of malignancies. Its principal pharmaceutical asset is GP2, a HER2/neu peptide immunotherapy currently being evaluated in a large-scale Phase III international clinical trial known as FLAMINGO-01 to help patients who have previously undergone surgery and trastuzumab-based treatments.